Genta Incorporated

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Genta Incorporated sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 12 completed early-phase tilt top decile by trial count

Genta Incorporated: 12 sponsored US clinical trials, none currently recruiting.

Genta Incorporated sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 4 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is CLL, with 1 trials.

Top-decile sponsor footprint

Genta Incorporated ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

A 90/100

12 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 1

Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsules

NCT01170975
COMPLETED Phase 3

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

NCT00518895
COMPLETED Phase 1

Genasense as a 2-hour Intravenous Infusion in Subjects With Solid Tumors

NCT00636545
COMPLETED Phase 1

Pharmacokinetic Study of Genasense in Subjects With Normal Renal Function, Mildly Impaired Renal Function, and Moderately Impaired Renal Function

NCT00543075
COMPLETED Phase 1

A Phase I Study of G3139 Subcutaneous in Solid Tumors

NCT00543231
COMPLETED Phase 1

Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

NCT00078234
COMPLETED Phase 2

Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00054808
COMPLETED Phase 3

Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

NCT00024440
COMPLETED Phase 1

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

NCT00021749
COMPLETED Phase 3

Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma

NCT00017602
COMPLETED Phase 2

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

NCT00017589
COMPLETED Phase 3

Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma

NCT00016263

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 2
Phase 3 4

Therapeutic Areas

CLL 1
Multiple Myeloma and Plasma Cell Neoplasm 1
Chronic Lymphocytic Leukemia 1

How the Genta Incorporated early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 12 completed (100%).

Phase mix: 4 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: CLL (1 trial), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Genta Incorporated: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Genta Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Genta IncorporatedAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Genta Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Genta Incorporated sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Genta Incorporated page

12 registered trials is a research-attention snapshot, not an endorsement of Genta Incorporated or any single study.

  • None of Genta Incorporated's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • CLL is the condition Genta Incorporated studies most, compare against other sponsors active in the same condition before evaluating a specific study. See CLL trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Genta Incorporated pipeline card: 12 registered trials from official public datasets.Report a data error.